Maximum Approved Dose of Ozempic
The maximum approved dose of Ozempic (semaglutide) for type 2 diabetes is 1 mg once weekly subcutaneously. 1
FDA-Approved Dosing Schedule
According to the official FDA prescribing information, the dosing algorithm is:
- Week 0-4: Start with 0.25 mg once weekly (initiation dose only, not effective for glycemic control)
- Week 4+: Increase to 0.5 mg once weekly
- Week 8+ (if needed): May increase to 1 mg once weekly (maximum dose)
The 0.25 mg starting dose serves solely as a tolerability step to minimize gastrointestinal side effects and has no glycemic efficacy 1.
Important Distinctions by Indication
For Type 2 Diabetes (Ozempic brand):
- Maximum dose: 1 mg weekly subcutaneously 1
- Approved for glycemic control and cardiovascular risk reduction 2
For Obesity/Weight Management (Wegovy brand - same molecule):
Oral Formulation (Rybelsus):
- Maximum dose: 14 mg daily for type 2 diabetes 2
- Higher doses (25-50 mg) studied for obesity but not yet approved 3
Clinical Context
Do not exceed 1 mg weekly when prescribing Ozempic for diabetes. While higher doses of semaglutide exist (2.4 mg for obesity as Wegovy, or investigational doses up to 16 mg), these are either different formulations/indications or remain experimental 5, 6. The 1 mg dose provides robust glycemic control with HbA1c reductions of approximately 1.9% and requires no renal dose adjustment 4.
The dose escalation schedule must be followed—jumping directly to 1 mg or accelerating titration increases gastrointestinal adverse events (nausea, vomiting, diarrhea) that occur in 60-65% of patients 2.